Valuation: Lavipharm S.A.

Capitalization 16Cr 19Cr 15Cr 14Cr 27Cr 1.75TCr 28Cr 175Cr 69Cr 830.85Cr 72Cr 71Cr 3.03TCr P/E ratio 2023
71.4x
P/E ratio 2024 14.9x
Enterprise value 19Cr 23Cr 18Cr 17Cr 31Cr 2.05TCr 33Cr 205.31Cr 81Cr 974.72Cr 84Cr 83Cr 3.56TCr EV / Sales 2023
3.1x
EV / Sales 2024 3.07x
Free-Float
38.34%
Yield 2023 *
-
Yield 2024 2.52%
More valuation ratios * Estimated data
Dynamic Chart
1 day-1.14%
1 week-2.75%
Current month-1.55%
1 month+2.14%
3 months+19.67%
6 months+16.46%
Current year-1.55%
More quotes
1 week 0.95
Extreme 0.948
0.99
1 month 0.91
Extreme 0.911
1
Current year 0.95
Extreme 0.948
1
1 year 0.65
Extreme 0.65
1
3 years 0.37
Extreme 0.368
1.01
5 years 0.35
Extreme 0.346
2.22
10 years 0.16
Extreme 0.162
2.22
More quotes
Manager TitleAgeSince
Director of Finance/CFO - 01/12/2021
Chief Tech/Sci/R&D Officer - -
Compliance Officer - -
Director TitleAgeSince
Director/Board Member - -
Director/Board Member 76 -
Chairman 86 01/01/2021
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-1.14%-2.75%+18.19%+119.04% 19Cr
-3.68%-7.04%-9.67%+55.09% 4.42TCr
-0.75%+2.27%+50.26% - 3.34TCr
+0.91%-1.50%+12.46%+116.80% 2.96TCr
-1.00%-5.92%-4.43%+29.45% 1.24TCr
-0.87%-2.42%-12.19%+97.67% 975.68Cr
-0.75%-3.77%+70.23%+40.07% 832.82Cr
-1.36%+0.46%+46.80%+127.08% 783.87Cr
-.--%+0.14% - - 678.76Cr
+0.58%-0.70%+39.38%-21.92% 666.8Cr
Average -0.82%-1.48%+23.45%+70.41% 1.59TCr
Weighted average by Cap. -1.25%-1.45%+17.47%+70.76%
See all sector performances

Financials

2023 2024
Net sales 5.09Cr 5.98Cr 4.72Cr 4.44Cr 8.26Cr 543.84Cr 8.86Cr 54Cr 22Cr 258.6Cr 22Cr 22Cr 943.7Cr 5.29Cr 6.21Cr 4.91Cr 4.61Cr 8.59Cr 565.37Cr 9.21Cr 57Cr 22Cr 268.84Cr 23Cr 23Cr 981.08Cr
Net income 18.71L 21.95L 17.34L 16.3L 30.35L 20Cr 32.55L 2Cr 79.05L 9.5Cr 82.32L 80.63L 35Cr 89.82L 1.05Cr 83.22L 78.27L 1.46Cr 96Cr 1.56Cr 9.61Cr 3.8Cr 46Cr 3.95Cr 3.87Cr 166.43Cr
Net Debt 2.4Cr 2.82Cr 2.23Cr 2.1Cr 3.9Cr 256.74Cr 4.18Cr 26Cr 10Cr 122.08Cr 11Cr 10Cr 445.51Cr 2.83Cr 3.32Cr 2.63Cr 2.47Cr 4.6Cr 302.57Cr 4.93Cr 30Cr 12Cr 143.87Cr 12Cr 12Cr 525.04Cr
More financial data * Estimated data
Logo Lavipharm S.A.
Lavipharm SA is a Greek commercial and industrial enterprise engaged in the development, manufacture, marketing and distribution of pharmaceutical, cosmetic and over-the-counter (OTC) products. Its main pharmaceutical products cover such categories as anti-inflammatory, asthma controlling, neurological, antiseptic, analgesic, dermatological and gastrointestinal therapies. Its cosmetic products are offered under the brand names of Castalia Soins Dermocosmetiques and Laviderm Active Technology and are used for skin, face and body care, as well as for scalp and hair problems. Its OTC products include cold and flu remedies, oral care, dermatological products, condoms, antiseptics, analgesics, laxatives and gynecology products. It is the parent company of Lavipharm Group of Companies. In January 2014, Robertet SA acquired together with CODIF the HITEX company, specialized in subcontracting of carbon dioxide extraction, from Lavipharm SA.
Employees
282
More about the company
Date Price Change Volume
20/26/20 0.9550 -1.14% 1,17,776
19/26/19 0.9660 -0.92% 1,71,811
16/26/16 0.9750 +1.25% 1,11,376
15/26/15 0.9630 -1.43% 1,54,708
14/26/14 0.9770 -0.31% 62,329

Delayed Quote Athens S.E., January 20, 2026 at 08:45 pm IST

More quotes